Latanoprost | Xalatamax eye drops 0.005%, 2.5 ml 3 pcs. pack

release form

eye drops

Packaging

3 bottles of 2.5 ml.

Pharmacological action

Anti-glaucoma drug for local use. Latanoprost is an analogue of prostaglandin F2 and a selective FP receptor agonist. It reduces intraocular pressure by increasing the outflow of aqueous humor and has an anti-glaucoma effect. The main mechanism of action of latanoprost is associated with an increase in uveoscleral outflow. It does not significantly affect the production of aqueous humor and does not affect the blood-ophthalmic barrier.

A decrease in intraocular pressure begins 3-4 hours after the administration of the drug, the maximum effect is noted after 8-12 hours, the duration of action is at least 24 hours.

Indications

Open angle glaucoma.

Increased intraocular pressure.

Contraindications

Individual hypersensitivity to latanoprost, benzalkonium chloride or other components of the

preparation age up to 18 years.

Use during pregnancy and lactation

Pregnancy

There is no sufficient experience with the use of the drug during pregnancy and lactation. The use of Latanoprost during pregnancy is possible only under the supervision of a doctor and only if the expected benefit to the mother outweighs the risk of possible side effects in the fetus.

Lactation

Latanoprost and its metabolites can pass into breast milk. If it is necessary to prescribe Xalatamax during lactation, breastfeeding should be discontinued.

Composition

Active ingredient: latanoprost - 0.050 mg.

Excipients: benzalkonium chloride - 0.20 mg sodium dihydrogen phosphate monohydrate - 4.60 mg sodium hydrogen phosphate - 4.74 mg sodium chloride - 4.10 mg purified water - 996.31 mg.

Dosage and administration

The drug is instilled in the conjunctival sac of the eye 1 drop 1 time per day in the evening.

When skipping a dose, the next one is administered as usual (i.e. do not double the dose).

With more frequent administration of the drug, its effectiveness decreases.

The duration of the course of treatment and the possibility of its recurrence are determined by the doctor.

Side effects

From the organ of vision

Eye irritation (burning sensation, sensation of sand in the eyes, itching, tingling and sensation of a foreign body), blepharitis, conjunctival hyperemia, pain in the eyes, increased iris pigmentation, transient point epithelial erosion, eyelid edema, corneal edema and erosion, conjunctivitis, lengthening, thickening, an increase in the number and strengthening of pigmentation, iritis and fluff / uveitis, keratitis, macular edema (including cystoid), a change in the direction of eyelash growth, sometimes causing eye irritation, blurred vision.

Dermatological reactions

Rash, darkening of the skin of the eyelids and local skin reactions of the eyelids.

From the nervous system

Dizziness headache.

From the respiratory system

Bronchial asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma), shortness of breath.

From the musculoskeletal system

Muscle pain, joint pain.

Other

Nonspecific chest pain.

Overdose

Symptoms: irritation of the mucous membrane of the eye, hyperemia of the conjunctiva or episcleras.

Treatment: carry out symptomatic therapy.

Storage conditions

Store in a dry, dark place at a temperature of 2 to 8 РC. Store the open bottle at a temperature not exceeding 25 РC.

Expiration

2 years, after opening the vial for 4 weeks.

Active ingredient

Latanoprost

Dosage form

Dosage form

eye drops

Jadran-Galenski Laboratories a.o., Croatia